Under the agreement, Noramco will supply active pharmaceutical ingredients (APIs) and SPI Pharma will provide excipients and co-processed drug delivery platforms.
“Both companies will jointly provide ‘proof-of-concept’ formulations that can be tech transferred to customers for scale up,” Noramco’s vice president of business development Anthony Ambrosini told us.
The offering will include generic, 505(b)(2), and new drug application (NDA) formations.
“We have no intention of manufacturing or marketing finished dosage formulations,” Ambrosini added.
According to the license agreements, customers will have the option to customise the formulations packages for APIs on a milestone basis.
The Wilmington, Delaware-headquartered firms have already observed interest from drugmakers looking for unique dosage forms in the controlled substance space.
The partnership offers manufacturers “access to innovative, ‘ready-for-scale-up’, ‘patient-friendly’ formulations that improve speed-to-market, reduce trial-and-error, offer product differentiation and life-cycle management opportunities,” Ambrosini told us.
Normaco had previously focused on opioid-based APIs until March last year when it added cannabinoids to its portfolio in response to growing industry demand.
Last month the firm boosted its API and intermediates supply through a partnership with AMPAC Fine Chemicals.